Phosphoglycerate mutase 1 (PGAM1) is a glycolytic
enzyme that increases glycolytic flux in the brain. In the present study, we examined the effects of PGAM1 in conditions of oxidative stress and ischemic damage in motor neuron-like (NSC34) cells and the rabbit spinal cord. A Tat-PGAM1 fusion
protein was prepared to allow easy crossing of the blood-brain barrier, and Control-PGAM1 was synthesized without the Tat
peptide protein transduction domain. Intracellular delivery of Tat-PGAM1, not Control-PGAM1, was achieved in a time- and concentration-dependent manner. Immunofluorescent staining confirmed the intracellular expression of Tat-PGAM1 in NSC34 cells. Tat-PGAM1, but not Control-PGAM1, significantly alleviated H2O2-induced oxidative stress, neuronal death,
mitogen-activated protein kinase, and
apoptosis-inducing factor expression in NSC34 cells. After
ischemia induction in the spinal cord, Tat-PGAM1 treatment significantly improved
ischemia-induced neurological impairments and ameliorated neuronal cell death in the ventral horn of the spinal cord 72 h after
ischemia. Tat-PGAM1 treatment significantly mitigated the
ischemia-induced increase in
malondialdehyde and 8-iso-prostaglandin F2α production in the spinal cord. In addition, Tat-PGAM1, but not Control-PGAM1, significantly decreased microglial activation and secretion of pro-inflammatory
cytokines, such as
interleukin (IL)-1β,
IL-6, and
tumor necrosis factor (TNF)-α induced by
ischemia in the ventral horn of the spinal cord. These results suggest that Tat-PGAM1 can be used as a therapeutic agent to reduce
spinal cord ischemia-induced neuronal damage by lowering the oxidative stress, microglial activation, and secretion of pro-inflammatory
cytokines, such as IL-1β,
IL-6, and TNF-α.